TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00934440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * First treatment: 10 milligram per kilograms (MG/KG) intravenously (IV) on Day 1every two weeks over 90 minutes.~* Second treatment: 10 MG/KG IV on Day 1 every two weeks over 60 minutes.~* Third and subsequent treatments: 10 MG/KG IV on Day 1 every two weeks over 30 minutes (minimum of two cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: * Dose level 1: 35 mg/m2/day for 7 days.~* Dose level 2: 55 mg/m2/day for 7 days.~* Dose level 3: 75 mg/m2/day for 7 days.~  * mg/m2/day = dose based on height and weight
Study: NCT01748240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine and oral vorinostat
Description: In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
Study: NCT02540278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Prevention PLUS
Description: PP+ has elven 45 minute lessons: (1) Getting Started, (2) Life Planning, (3) Healthy Relationships, (4) Relationship Violence, (5) Family Planning and Contraceptives, (6) Myths and Stereotypes, (7) HIV Disease and AIDS, (8) Recognizing and Reducing Risk, (9) Peer and Media Pressures, (10) Human Immunodeficiency Virus (HIV)/Sexually Transmitted Disease (STD) Testing and Community Resources, and (11) Steps to Success.
Study: NCT03248349

Intervention type: DRUG
Intervention: Pharmacokinetics
Description: * Blood samples are drawn for pharmacokinetic properties of antibiotics during routine care treatment~* Blood samples for relevant covariates of drug disposition (kidney function, liver enzymes, C-reactive protein (CRP), albumin)~* Whole blood is stored for DNA analysis~* Urine is drawn from catheter for more detailed estimation of glomerular filtration rate and drug metabolite analysis
Study: NCT03396952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00597597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
Study: NCT00461071

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Self-help for Bulimia nervosa
Description: bibliotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Self-help for Bulimia nervosa
Description: bibliotherapy
Study: NCT02249000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOVALVE prosthesis
Description: Transcatheter Aortic Valve Replacement (TAVR)
Study: NCT04109885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracervical injection
Description: 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prochlorperazine and diphenhydramine.(Standard Treatment)
Description: Intravenous administration of prochlorperazine and diphenhydramine.
Study: NCT02447315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study: NCT01402297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apocynin and placebo nebulization
Description: 6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) and 0,9% NaCl as placebo, has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
Study: NCT01430650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral strogen
Description: 2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal strogen
Description: One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.
Study: NCT01505907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXB909
Description: CXB909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXB909
Description: CXB909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXB909
Description: CXB909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXB909
Description: CXB909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXB909
Description: CXB909
Study: NCT04537689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Ixekizumab for 6 months, given 160mg at weeks 0, followed by 80mg at 2, 4, 6, 8, 10 and 12, then 4 weekly till 6 months. Given subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral tablet up to 15mg per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: Oral capsule up to 200mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: Oral capsule up to 25mg per day
Study: NCT00145977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: alendronate 70 mg once weekly

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Citrate
Description: 600 mg of calcium citrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Citrate
Description: 600 mg of calcium citrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 500 mg of Vitamin D consumed with the evening meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 500 mg of Vitamin D consumed with the evening meal.
Study: NCT01212380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV infusion lasting 30 minutes. Will be administered IV at a specified dose in mg/m2 QDx2 weekly for 3 weeks (days 1, 2, 8, 9, 15, and 16). The first and second dose will always be administered at 20 mg/m2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytokine Assessment
Description: TNF-α,IFN-γ,IL-6,IL-8,IL-10,and IL-1β pre-dose, completion, 30 minutes, 2 hours, 6 hours, and approximately 24 hours from initiation of therapy on days 1 and 8 of treatment. These will be assessed utilizing standard ELISA or flow cytometry methodology. Other cytokines or soluble factors may be assessed that relate to drug toxicity or response. After 6 patients are examined in each group, the time points or number of cytokines examined may be changed to decrease time points examined. Cytokines will be examined by a multiplex flow cytometry assay or ELISA. Other cytokines, chemokines, or soluble factors may be assessed on residual material not used for these studies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Studies
Description: Based upon our preliminary data changes occuring in vivo during carfilzomib treatment will be determined and if their occurrence correlates with both clinical response and development of cytokine release. These studies will be performed from CD19 selected CLL cells at screening, pre-treatment, 4 hours, and 24 hours post-therapy on days 1 and 8 of treatment; end of therapy evaluation, and at time of relapse (in responding patients). These studies will include assessment of NF-κB (p50/p65 binding; I-κB level, P-I-κB level, select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), p73, and ER stress response. Standard Western Blot, EMSA, RT-PCR will be done to complete these studies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proteosome Inhibition Assessment
Description: Proteosome inhibition on CLL cells will be examined at screening, pre-treatment and post-treatment (immediately after completion of drug) days 1, pre-treatment day 2, day 3 (optional), day 5 (optional),pre and post-treatment days 8, pre and post-treatment days 9, day 10 (optional),day 12 (optional), and day 15 (optional).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Studies
Description: Germ line DNA from a buccal swab and bone marrow fibroblasts will be obtained at baseline screening for possible examination of SNP polymorphisms that may correlate with response and toxicity to carfilzomib therapy. Tumor DNA will be derived from samples obtained at baseline for the p53 mutational studies. SNPs related to drug metabolism, response, or toxicity to therapy, cytokine release, and tumor biology may be examined. Other SNPs may be used in the future. Given the potential for contamination in the recipient, recipient DNA from a buccal swab and/or saliva will be obtained at baseline screening for examination of SNP polymorphisms that may correlate with response, toxicity, and pharmacokinetics.
Study: NCT00838032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
Study: NCT02027090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine dose icotinib
Description: Icotinib is administered 125 mg three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher dose icotinib
Description: After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.
Study: NCT04792242

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cv line insertion
Description: Svo2 and central venous pressure measurements

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cv line insertion
Description: Svo2 and central venous pressure measurements

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary catheter insertion
Description: urine output measurement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary catheter insertion
Description: urine output measurement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial line
Description: Arterial blood gases measurment
Study: NCT03399201

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: induction with the intravenous anesthetic (Propofol) and maintenance with the inhalational anesthetic (Sevoflurane)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuraxial anesthesia
Description: Spinal anesthesia will be applied via the local anesthetic ( Bupivacaine).
Study: NCT01646632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Description: the experimental intervention included group- based progressive resistance training, balance training, and functional training, two times a week, one hour sessions, lasting 16 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle counseling
Description: the control intervention included recreational sessions, including talks, video's, music, board games etc. No physical activity was involved in the control intervention.
Study: NCT03399201

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometer
Description: Pulmonary function will be evaluated via the portable spirometer (MIR Spirodoc, Spirodoc®, Roma, Italy)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometer
Description: Pulmonary function will be evaluated via the portable spirometer (MIR Spirodoc, Spirodoc®, Roma, Italy)
Study: NCT03812822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole
Description: Custom-made insoles which support the foot at subtalar neutral position
Study: NCT03873090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBRT
Description: hypofractionated accelerated RT for prostate cancer with FFF (Free Flattened Filter) beam. The schedule will be \[ 4 x 9.5 Gy = 38 Gy \] delivered in 5 alternative days, corresponding to an NTD2 between 95 and 119 Gy for an α/β estimate between 3 and 1.5 Gy.
Study: NCT00744042

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: asfotase alfa
Study: NCT01559740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
Study: NCT02717832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperinsulinemic-euglycemic clamp
Study: NCT05800301

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wharton's jelly derived mesenchymal stemcells
Description: The WJ-MSCs suspension from the culture was delivered to the operating room by cold chain and used within 24 h. A total of 1.5 ml of the WJ-MSC suspension was immediately injected into the deep subtenon space of each eye.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wharton's jelly derived mesenchymal stemcells
Description: The WJ-MSCs suspension from the culture was delivered to the operating room by cold chain and used within 24 h. A total of 1.5 ml of the WJ-MSC suspension was immediately injected into the deep subtenon space of each eye.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnovision
Description: Specifically designed helmets producing high-frequency repetitive electromagnetic stimulation (MagnovisionTM, Bioretina Biotechnology, Ankara, Türkiye) stimulated the retinas and visual pathways in both eyes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnovision
Description: Specifically designed helmets producing high-frequency repetitive electromagnetic stimulation (MagnovisionTM, Bioretina Biotechnology, Ankara, Türkiye) stimulated the retinas and visual pathways in both eyes.
Study: NCT04620876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bimodal high resolution imaging of the retina
Description: The protocol consists of performing an Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT).The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
Study: NCT05032469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet
Study: NCT01064375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)
Description: Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation
Study: NCT02234050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin will be given as a 24-hour infusion every 3 weeks at a starting dose of 1.5 mg/m2 body surface area (BSA), until one of the treatment withdrawal criteria has been met.

Intervention type: OTHER
Group type: OTHER
Intervention: Local standard of care
Description: Left to the discretion of the investigator
Study: NCT01064375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)
Description: Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)
Description: Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derma Vax (electroporation device)
Description: Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derma Vax (electroporation device)
Description: Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derma Vax (electroporation device)
Description: Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF will be given for 4 consecutive days starting the day before the vaccination as an intradermal/subcutaneous administration of 150 ug of GM-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
Study: NCT03476005

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: proficiency based progression training
Description: proficiency based progression training supported by technology enhanced learning
Study: NCT03869463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: Participants will complete 8 weeks of computerized cognitive training through the Peak platform on mobile devices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training
Description: Participants will complete 8 weeks of computerized cognitive training through the Peak platform on mobile devices.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This group will not receive computerized cognitive training.
Study: NCT01232036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage 500mg
Description: Single Oral Dose of

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-018 500mg
Description: Single Oral Dose of

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No administration of Drug
Study: NCT02644616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolvaptan+torasemide
Description: tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo+torasemide
Description: placebo 15mg/d po(10 days) +torasemide 20mg/d iv
Study: NCT01755026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin
Description: 2 gram dose for pre-operative prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefazolin
Description: 4 gram dose for pre-operative prophylaxis
Study: NCT02238184

Intervention type: DRUG
Intervention: Atrovent®

Intervention type: DRUG
Intervention: Ventilat®
Study: NCT00973011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCFD4514S
Description: Intravitreal escalating dose
Study: NCT02971033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg ezetimibe
Description: Participants assigned to this intervention will receive 20mg per day of ezetimibe for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants assigned to this intervention will receive placebo every day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg ezetimibe
Description: Participants assigned to this intervention will receive 40mg per day of ezetimibe for 12 weeks.